This education session is being delivered as part of the GP Fellowship Education Programme and is open to Cambridgeshire and Peterborough GPs who are enrolled on the GP Fellowship Scheme, or who are within their first 5 years of practice.

 

For our June education session, Dr Jessica Randall-Carrick will be joining us to talk about:

The New Drugs & Technologies for Diabetes -SGLT2-I, GLP1-analogues & CGMs (NICE Guidelines updated March 2022)

NICE Guidelines for diabetes were updated end of March 2022 with big changes to how we should escalate pharmacological treatment, using the ‘newer’ SGLT2-inhibitors ‘flozins’ much earlier on.

This session will go through these guidelines in a fun and interactive way using case studies to help learners identify which patients and when should have these new drugs.

GLP1-analogues and Diabetes technologies will also be discussed, and their place in our management supporting those living with diabetes.

Learning Objectives:

  1. To know how to consult with a patient to know when to start a SGLT2-inhibitor, explain to the patient how it works and when to review it’s efficacy, all placed in the context of the patient’s current diet, past medical history & cardiovascular risk.
  2. To understand that SGLT2-inhibitors are now in heart failure and CKD NICE guidelines, and when these are to be used.
  3. To know how to consult with a patient to know when to start a GLP1-analogue, explain to the patient how it works and when to review it’s efficacy, all placed in the context of the patient’s current diet, weight & lifestyle.
  4. To know how use of the Diabetes technologies has changed this year, and when we can start to use these within General Practice in C&P (not yet!)

Speaker Profile:

Dr Jessica Randall-Carrick is an Early Career GP with a particular interest in promoting health equity. She is the C&P ICS Clinical Lead for Diabetes & Obesity, and Co-Leads CVD Prevention with Dr Val Thomas (C&P Public Health Consultant).

As premature cardiovascular disease (CVD) is the leading cause of perpetuating health inequality, Jessica is passionate to help improve our detection and care of those patients at high risk of, or living with, risk factors for CVD – including hypertension, hyperlipidaemia, diabetes, excess weight & obesity. Jessica really values the individual opportunistic interventions of every consultation, as well as the more strategic Population Health Management approach, and she hopes that her enthusiasm for both will be shared to others through her energetic teaching & passion

 

This session will take place via Zoom. After booking, you will receive joining instructions approximately 24 hours before the event.